The second bite of the apple in plastic surgery is the payday that comes after the payday. When you sold your practice to a private equity-backed group, part of your price was rolled into equity in the buyer. Years later, when the sponsor sells the platform, that equity is valued again. Sometimes it’s worth several times what you rolled. Sometimes it’s worth much less.
Plenty is written about selling a practice. Very little is written for the surgeon who already sold and now hears their platform is going to market. This guide explains how the second bite works, how your payout is calculated, what drives the outcome, how it’s taxed, whether to roll again and what to negotiate at your first sale to protect it. It builds on our main guide to plastic surgery rollover equity.
Key takeaways
- The second bite is the payout on your rollover equity when the private equity sponsor sells or recapitalizes the platform.
- Your payout depends on the sale price, the platform’s debt, any preferred equity ahead of you and your class of units.
- Many platforms are approaching their exit window. FOCUS describes a five-to-seven-year hold period in physician practice deals (FOCUS).
- Rollover equity “may lose some or all of its value,” so the second bite isn’t guaranteed (Roetzel & Andress).
What is the second bite of the apple in plastic surgery?
The second bite of the apple in plastic surgery is the money a surgeon receives from their rollover equity when the private equity sponsor sells the platform they joined. The first bite is the cash paid at the original sale. The second comes years later, and its size depends on how much the platform grew and how the sale is structured.
It’s the main reason surgeons accept rollover equity. Private equity platforms often buy practices at add-on multiples and hope to sell the combined group at a higher platform multiple. If that works, every dollar of earnings you contributed is revalued upward, and your equity shares in the gain. Our guide to plastic surgery practice EBITDA multiples explains that multiple gap.
When does the second bite happen?
When the sponsor sells the platform, usually to a larger private equity firm or strategic buyer, or recapitalizes it by bringing in new investors. Private equity funds hold companies for a limited period, often several years, so the timing depends on when the platform was formed and when you joined.
PitchBook reported that the median US private equity hold reached 3.4 years at the end of 2024, the longest in over nine years, and that more than 30% of PE-backed companies had been held at least five years. Surgeons who joined a platform late in its hold may reach their second bite within a year or two of selling.
How is your second bite calculated?
Through the equity waterfall. The platform’s sale price goes first to repay debt, then transaction costs, then any preferred equity or preferred return, and what remains is shared among common equity holders by ownership percentage. Your payout is your share of what’s left, not a share of the headline price.
Here’s a hypothetical example, with illustrative figures only:
| Step | Amount |
| Platform sale price (enterprise value) | $400,000,000 |
| Less: debt repaid | $180,000,000 |
| Less: transaction costs | $10,000,000 |
| Equity value available | $210,000,000 |
| Your ownership (common units) | 1.5% |
| Your gross payout | $3,150,000 |
| What you originally rolled | $1,500,000 |
In this example your stake roughly doubled. But change one input, such as $60 million more debt or a preferred return owed to the sponsor first, and the result changes quickly. That’s why the waterfall, not the headline price, is the number to understand.
How do preferences change the second bite in plastic surgery deals?
Preferences decide who gets paid first. If the sponsor holds preferred equity or is owed a preferred return, that amount comes out of the equity value before common holders share the rest. In a strong sale the effect may be modest. In a weak one, preferences can absorb most of the value, leaving little for surgeons holding common units.
Using the hypothetical above, suppose the sponsor were owed a $40 million preference before common holders. Equity available to common units would fall from $210 million to $170 million, and a 1.5% common stake would pay about $2.55 million instead of $3.15 million. The second bite of the apple in plastic surgery deals often turns on terms like this, which is why you should ask about them before you roll.
Can there be a third bite?
Yes, if you roll again into the new owner and it later sells too. Each roll gives you another chance at upside and another round of risk. Surgeons who are still early in their careers sometimes welcome a third bite. Those nearing retirement usually prefer to take more cash at the second.
7 honest truths about the second bite
1. It depends on growth, not hope
The platform has to grow earnings and sell at a good multiple. If it stalls, the second bite shrinks.
2. Debt comes first
Every dollar of debt is repaid before equity holders see anything. A highly indebted platform needs more growth for your stake to rise.
3. Your class of equity matters
Common units, preferred units and management incentive units are paid differently. Know which you hold and what sits ahead of it.
4. You probably can’t control the timing
The sponsor decides when to sell. Drag-along rights usually require you to sell on the same terms.
5. You may be asked to roll again
Buyers of platforms often want surgeons to reinvest part of their proceeds, starting a third bite.
6. Leaving early can cost you
Roetzel & Andress notes rollover equity is often subject to forfeiture or a reduced price if the seller stops providing services. Check your terms before changing plans.
7. There may be nothing to collect before the exit
Distributions before a sale aren’t guaranteed. Roetzel & Andress says plainly: “There is no guarantee that cash distributions will be made.”
Should you roll again or cash out?
It depends on how much you need in cash, your confidence in the new owner, your age and plans, and the tax cost of each option. Rolling again keeps upside and defers tax, but resets the risk and the clock. Cashing out locks in your result. Many surgeons do a mix.
Questions that help decide:
- How much of your net worth is already tied up in this platform?
- Do you plan to keep operating for another full hold period?
- What does the new sponsor plan to do, and how much debt will it add?
- What employment and non-compete terms come with rolling again?
- What’s the tax difference between rolling and cashing out?
How is the second bite taxed?
Usually, the gain on your rollover equity is taxed when it’s sold for cash, since the original rollover was typically tax-deferred. If you roll again into the new owner, part of the gain may be deferred again if the structure qualifies. The details depend on how your equity was structured, so get tax advice early.
Alston & Bird explains that most rollover structures rely on Section 721 for partnerships or Section 351 for corporations, and that the way cash and equity are allocated can trigger unexpected gain. Roetzel & Andress lists events, such as certain distributions, that can cause deferred gain to be recognized. This guide isn’t tax advice.
What happens to your employment at the second bite?
A new owner may ask you to sign a new employment agreement, with new compensation, a new term and a new non-compete. That’s a negotiation, not a formality. Your bargaining power comes from your importance to the platform: surgeons who produce well and help recruit are the ones buyers most want to keep.
Read any new agreement as closely as your first. Our guide to the post-close employment agreement for surgeons covers compensation formulas, clinical autonomy and non-competes, all of which may be reopened when the platform sells.
What should you negotiate at your first sale to protect the second bite?
Clarity on the entity and class of equity you receive, limits on debt or dilution where possible, information rights so you receive annual financials and valuations, tag-along rights if the sponsor sells part of its stake, fair treatment if you’re terminated without cause, and clear forfeiture and repurchase terms. These are much easier to win before you sign than after.
A short list to raise with your attorney:
- Which entity issues your equity, and what’s its capital structure?
- Does sponsor equity carry a preference or preferred return?
- Will you receive annual financial statements and equity valuations?
- What happens to your equity if you leave, retire, become disabled or die?
- Do you get tag-along rights if the sponsor sells part of its stake?
- How are new equity issuances to other surgeons handled?
What if you already sold and your platform is going to market?
Act early. Reread your operating agreement, ask for the expected waterfall, understand your roll-again options, review any new employment terms and hire your own attorney and tax adviser. The platform’s advisers represent the platform. Treat the event as a second sale, because financially it is one.
Timing is tight once a sale process starts, and surgeons often receive documents with short deadlines. Knowing your rights before the process begins gives you room to ask questions and negotiate. For how buyers evaluate platforms and practices, see our guide to private equity plastic surgery practices.
Frequently asked questions
What does second bite of the apple mean in a practice sale?
It means the second payout a surgeon receives from a practice sale. The first bite is the cash at closing. The second comes when the private equity sponsor later sells the platform and the surgeon’s rollover equity is paid out, ideally at a higher value because the platform has grown.
How much is my second bite likely to be worth?
It depends on the platform’s sale price, its debt, transaction costs, any preferred equity and your ownership percentage and class of units. It can be several times your original rollover or much less. Ask for an expected waterfall to understand your likely range before the sale closes.
When will my platform be sold?
Usually several years after the sponsor bought it. FOCUS describes a five-to-seven-year hold in physician practice deals, and PitchBook reported a median US private equity hold of 3.4 years at the end of 2024. Ask your sponsor about its fund timeline to estimate your window.
Do I have to sell my equity when the platform sells?
Often yes. Drag-along rights in most operating agreements require minority holders to sell on the same terms as the sponsor. You may, however, be offered the option to roll part of your proceeds into the new owner. Check your operating agreement for the specific rights and obligations.
Is the second bite taxed as capital gains?
Often, but not always. The gain on rollover equity is typically taxed when sold for cash, and its treatment depends on how the equity was structured and held. Rolling again may defer part of the gain if the structure qualifies. Get advice from a tax adviser before the transaction closes.
What happens to my rollover equity if I’ve left the platform?
It depends on your agreements. Rollover equity may be subject to forfeiture, repurchase at a discount or a reduced price if you stopped providing services, especially if you left without good reason. If you kept your equity, you usually participate in the sale like other holders.
Second bite of the apple in plastic surgery: the bottom line
The second bite of the apple in plastic surgery can be the most valuable part of a sale, or a disappointment. Understand the waterfall, the debt and your class of equity, negotiate protections at your first sale, and treat the platform’s exit as the second sale it really is.
| Is your platform heading to market? Get the Plastic Surgery Exit Report newsletter for quarterly deal updates, or book a confidential conversation with the plastic surgery team at Olympic M&A. Disclosure: Plastic Surgery Exit Report is published in partnership with Olympic M&A, a healthcare M&A advisory firm. |
